2914 On Other Exchanges
2914 is not on other exchanges.

japan tobacco inc (2914) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JAPAN TOBACCO INC (2914)

Related News

No related news articles were found.

japan tobacco inc (2914) Related Businessweek News

View More BusinessWeek News

japan tobacco inc (2914) Details

Japan Tobacco Inc., together with its subsidiaries, manufactures and sells tobacco products, prescription drugs, and processed foods in Japan. The company operates through four segments: Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food business. It sells tobacco products approximately in 130 countries under the Winston, Camel, MEVIUS, and LD brands. The company engages in the research and development, manufacture, and sale of prescription drugs in the fields of metabolic diseases, viral infection, and autoimmune/inflammatory diseases. It manufactures and sells staple food products, including frozen noodles, frozen rice, packed-cooked rice, and frozen baked bread; bakery products; and seasonings, including yeast extracts and oyster sauce. The company was founded in 1898 and is headquartered in Tokyo, Japan.

39,000 Employees
Last Reported Date: 04/3/18
Founded in 1898

japan tobacco inc (2914) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

japan tobacco inc
Japan Tobacco Inc. Announces Preliminary Revenue and Production Results for the Quarter and Month Ended March, 2018

Japan Tobacco Inc. announced preliminary revenue and production results for the quarter and month ended March, 2018. For the quarter, the company reported Japanese domestic cigarette revenue of JPY 116.7 billion against JPY 136.3 billion for the same period a year ago. For the month, the company reported Japanese domestic cigarette revenue of JPY 43.2 billion against JPY 50.1 billion for the same period a year ago. For the quarter, the company reported cigarette sales volume of JPY 19.5 billion cigarettes against JPY 23.0 billion cigarettes for the same period a year ago. For the month, the company reported cigarette sales volume of JPY 7.2 billion cigarettes against JPY 8.5 billion cigarettes for the same period a year ago.

Japan Tobacco Inc. Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2017; Provides Earnings Guidance for the Year 2018

Japan Tobacco Inc. announced audited consolidated earnings results for the year ended December 31, 2017. For the period, on consolidated basis, the company reported revenue of JPY 2,139,653 million compared to JPY 2,143,287 million a year ago. Operating profit was JPY 561,101 million compared to JPY 593,329 million a year ago. Profit before income taxes was JPY 538,532 million compared to JPY 578,237 million a year ago. Profit for the year was JPY 396,749 million compared to JPY 425,773 million a year ago. Profit attributable to owners of the parent company was JPY 392,409 million compared to JPY 421,695 million a year ago. Diluted earnings per share were JPY 218.97 compared to JPY 235.33 a year ago. Net cash flows from operating activities were JPY 419,212 million compared to JPY 376,549 million a year ago. Purchase of property, plant and equipment was JPY 123,726 million compared to JPY 101,072 million a year ago. Purchase of intangible assets was JPY 16,412 million compared to JPY 9,929 million a year ago. Adjusted operating profit was JPY 585.3 billion compared to JPY 586.8 billion a year ago. On a consolidated basis, the company targets to grow its KPI which is adjusted operating profit at constant FX by 3.7% year on year, driven by a persistent level of profit growth in the international tobacco business and continuous profit contribution in the pharmaceutical and processed food businesses. On a reported basis, adjusted operating profit is forecast to grow 2.5%, as the company expects a slight negative FX impact mainly due to the yen appreciation.

Japan Tobacco Inc. Signs an Exclusive License Agreement with Rohto Pharmaceutical Co., Ltd. for the Development and Commercialization in Japan

Japan Tobacco Inc. announced that the company has signed an exclusive license agreement with ROHTO Pharmaceutical Co. Ltd. for the development and commercialization in Japan of JT's original compound, JTE-052, for the treatment of the specific disease in ophthalmology. JTE-052 inhibits Janus kinase, which plays an important role in immunologically activating signal transduction. JTE-052 works by controlling excessive activation of immunoreaction and relieves autoimmune and allergic disease symptoms. Under the terms of the agreement, ROHTO Pharmaceutical will develop and commercialize JTE-052 for the treatment of the specific disease in ophthalmology in Japan. ROHTO Pharmaceutical will start its development from non-clinical stage. The conclusion of the agreement is not expected to have a significant impact on the consolidated business performance of JT in the fiscal year ending December 2018.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

2914 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2914.
View Industry Companies

Industry Analysis


Industry Average

Valuation 2914 Industry Range
Price/Earnings 13.7x
Price/Sales 2.5x
Price/Book 1.9x
Price/Cash Flow 12.7x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact JAPAN TOBACCO INC, please visit www.jt.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.